Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

  • US 9,814,708 B2
  • Filed: 02/16/2016
  • Issued: 11/14/2017
  • Est. Priority Date: 09/18/2012
  • Status: Active Grant
First Claim
Patent Images

1. An extended-release pharmaceutical formulation comprising 6 to 24 mg of d6-tetrabenazine and between about 5% and about 20% by weight, based on the weight of the formulation, of a poly(ethylene oxide) polymer, wherein upon administration to a subject:

  • the formulation provides a reduction in dose relative to a formulation comprising non-deuterated tetrabenazine; and

    maintains at least the same AUC of the total combined amount of d6

    -dihydrotetrabenazine and d6

    -dihydrotetrabenazine relative to α

    -dihydrotetrabenazine and β

    -dihydrotetrabenazine of the formulation comprising non-deuterated tetrabenazine.

View all claims

    Thank you for your feedback